Key Takeaways
- UBS has moved Tesla ($TSLA) from a Sell rating to Neutral, maintaining a $352 price objective
- Shares have tumbled over 21% year-to-date in 2026, lagging significantly behind major indices
- The firm projects just 1.6 million unit deliveries for 2026 with modest expansion through decade’s end
- Robotaxi deployment remains behind schedule; Optimus humanoid robot timeline appears overly aggressive
- Lead analyst emphasizes Tesla’s valuation reflects narrative power rather than current financial metrics
UBS has reversed course on Tesla (TSLA), elevating the electric vehicle maker from Sell to Neutral in response to what it characterizes as a more equilibrated risk-reward dynamic after this year’s substantial price correction.
Joseph Spak, the UBS analyst covering the automaker, maintained his $352 valuation target while making the ratings adjustment. The move follows a year-to-date decline exceeding 21% for Tesla shares, substantially underperforming broader equity benchmarks.
According to Spak, the stock’s present valuation represents a more reasonable balance between immediate challenges and the company’s extended-horizon prospects in physical artificial intelligence applications.
Multiple factors have pressured the shares downward. Softening electric vehicle market conditions, disappointing first-quarter energy division results, margin compression, and escalating capital expenditure requirements have collectively dampened investor enthusiasm.
Development momentum for Tesla’s flagship future initiatives — the autonomous robotaxi platform and Optimus humanoid robot program — has likewise disappointed relative to earlier projections.
Despite upgrading the rating, Spak offered a realistic assessment of near-term prospects. He cautioned that the shares “may continue to exhibit high volatility” and emphasized that price action reflects investor sentiment and strategic narratives more than fundamental business performance.
Regarding specific projections, UBS anticipates approximately 1.6 million vehicle deliveries throughout 2026 — essentially unchanged from the prior year. The firm models a compound annual growth rate of 7%, reaching roughly 2 million units by 2030. This forecast falls considerably below the Street consensus estimate approaching 3 million vehicles.
Spak attributes this conservative outlook to intensifying pressure from Chinese competitors, subdued domestic EV adoption rates, and Tesla’s limited model refresh pipeline.
Autonomous Taxi Rollout Faces Execution Challenges
Tesla had previously communicated expectations for robotaxi operations across nine metropolitan areas during 2026’s first half. However, Spak expressed skepticism given the deliberate pace observed in Austin deployment efforts.
He anticipates minimal near-term scaling. Over longer horizons, UBS continues to recognize Tesla’s potential for delivering competitively priced transportation services and capturing significant U.S. autonomous ride-hailing market share.
Humanoid Robot Production Likely Years Behind Musk Projections
Regarding Optimus, Spak adopted a reserved posture. He projected the initiative “will take longer than Musk’s stated targets” and highlighted supply chain vulnerabilities stemming from heavy dependence on China-sourced components.
UBS models approximately 5,000 Optimus units during 2027, expanding to 30,000 by 2030. These figures represent a fraction of Musk’s stated ambitions for high-volume manufacturing commencing in the coming year.
From a valuation perspective, applying a 150x price-to-earnings ratio, Tesla’s trading level implies approximately $2.33 in 2027 earnings per share. UBS forecasts $2.35; the consensus estimate stands at $2.47.
Tesla currently trades at 325 times earnings, which numerous market data platforms characterize as elevated relative to intrinsic value assessments.
Recent regulatory developments brought positive news as the Netherlands granted approval for Tesla’s Full Self-Driving system on both highways and urban roadways — marking the first such European authorization. Cantor Fitzgerald referenced this milestone when reaffirming its Overweight rating alongside a $510 price target.
